Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer’s disease |
| |
| Institution: | 1. Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan;2. Institute of Cyclotron and Drug Discovery Research, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Fukushima 963-8052, Japan;3. Preparing Section for New Faculty of Medical Science, Fukushima Medical University, Fukushima 960-1295, Japan;4. Department of Radiological Sciences, School of Health Science, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan;5. Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Itabashi, Tokyo 173-0015, Japan;6. Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan;7. National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan;8. Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima 960-1295, Japan;1. School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University, 47500 Subang Jaya, Selangor, Malaysia;2. Department of Biomedical Science, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia;3. School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, 47500 Subang Jaya, Selangor, Malaysia;4. Photonics Research Centre, University of Malaya, 50603 Kuala Lumpur, Malaysia;5. Department of Biomedical Imaging, University of Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia;6. Animal Experimental Unit, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia;1. Pharmacology and Clinical Evaluation Division, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain;2. Nuclear Medicine Department, idcsalud Hospital Albacete, Albacete, Spain;3. Clinical Biostatistics Department, Hospital Ramón y Cajal, Madrid, Spain;4. Neurology Department, Hospital Ruber Internacional, Madrid, Spain;5. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany;1. Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity St James'' Cancer Institute, Trinity College Dublin, Dublin, Ireland;2. Molecular Radiotherapy and Innovative Therapeutics, INSERM UMR1030, Gustave Roussy Cancer Campus, Université Paris Salcay, Villejuif, France;3. Department of Psychiatry School of Medicine, Trinity College Dublin, Dublin, Ireland;1. CSIRO Health and Biosecurity, Brisbane, Australia;2. Department of Molecular Imaging, Austin Health, Melbourne, Australia;3. National Ageing Research Institute, Parkville, Victoria, Australia;4. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia;5. Department of Medicine, University of Melbourne, Melbourne, Australia;1. Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA;2. Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA;3. Department of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USA;4. Department of Neurology, University of California, Davis, CA, USA;5. Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia;6. Department of Neurology, University of Pittsburgh, PA, USA;7. Department of Psychiatry, University of Pittsburgh, PA, USA;8. Department of Radiology, Mayo Clinic, Rochester, MN, USA;9. Alzheimer''s Disease Center, Department of Pathology, University of California Davis, CA, USA;10. Alzheimer''s Disease Research Center, University of Pittsburgh, PA, USA;11. Department of Pathology, University of Pittsburgh, Pennsylvania, USA;12. Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA;13. Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA;14. The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia;15. Department of Radiology, University of Pittsburgh, PA, USA;p. Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia;q. Biomedical Isotope Facility, MBIB Division, Lawrence Berkeley National Laboratory, CA, USA;r. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA;s. Department of Neurology, Mayo Clinic, Rochester, MN, USA;t. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA |
| |
| Abstract: | PurposeA standardized method for quantification is required for analyzing PET data, but such standards have not been established for tau PET imaging. The Centiloid scale has recently been proposed as a standard method for quantifying amyloid deposition on PET imaging. Therefore, the present study aimed to apply the Centiloid scale to 18F-THK5351 PET imaging in Alzheimer’s disease (AD).MethodsWe acquired 18F-THK5351 PET, 11C-PiB PET, and MR images from 47 cognitively normal (CN) individuals and 28 patients with AD with mild to moderate dementia. PET images were spatially normalized to Montreal Neurological Institute space. The PET signals were then normalized using the signal in the reference volume of interest (VOI). Target VOI for specific 18F-THK5351 retention in AD was extracted by voxel-wise comparison of PET images between the 47 CN individuals and 16 AD patients with moderate dementia. Scale anchor points were defined by the CN individuals as 0-anchor points and by that of the average of the typical AD patients as 100-anchor points.ResultsSpecific retention of 18F-THK5351 was predominant in the angular gyrus, inferior temporal cortex, and parieto-occipital regions in patients with AD. Standardized uptake value ratio (SUVR) of 1.227 and 1.797 were defined as 0- and 100-anchor points, respectively. 18F-THK5351 PET data could be expressed using the Centiloid scale, with the SUVR of the 18F-THK5351 PET images converted to Centiloid using our VOI, the standard Centiloid reference VOI, and the following equation: Centiloid = 169.0 × SUVR–204.6.ConclusionCentiloid methods can be applied to tau PET imaging using 18F-THK5351. |
| |
| Keywords: | PET Tau Alzheimer’s disease Centiloid scale Quantification |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
